

1 **Title:** Cardiovascular Disease Risk Prediction Models in Haiti: Implications for Primary Prevention in Low-
2 Middle Income Countries

3 **Authors:** Lily D Yan MD MSc^{1,2}, Jean Lookens Pierre MD³, Vanessa Rouzier MD^{2,3}, Michel Théard MD⁴,
4 Alexandra Apollon MT³, Stephano St-Preux MS³, Justin R Kingery MD PhD^{1,2}, Kenneth A Jamerson MD⁵,
5 Marie Deschamps MD³, Jean W Pape MD^{2,3}, Monika M Safford MD¹, Margaret L McNairy MD MSc^{1,2}

6 **Affiliations**

7 1. Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York,
8 New York, USA

9 2. Center for Global Health, Weill Cornell Medicine, New York, New York, USA

10 3. Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-
11 Prince, Haiti

12 4. Collège Haïtien de Cardiologie, Port-au-Prince, Haiti

13 5. Division of Cardiovascular Disease, Department of Medicine, University of Michigan, Ann Arbor,
14 Michigan, USA

15

16 **Corresponding Author**

17 Lily D Yan, liy9032@med.cornell.edu

18 Word count: 2009

19

20

21 **Abstract**

22 **Background**

23 Cardiovascular diseases (CVD) are rapidly increasing in low-middle income countries (LMICs). Accurate
24 risk assessment is essential to reduce premature CVD by targeting primary prevention and risk factor
25 treatment among high-risk groups. Available CVD risk prediction models are built on predominantly
26 Caucasian, high-income country populations, and have not been evaluated in LMIC populations.

27 **Objective**

28 To compare the predicted 10-year risk of CVD and identify high-risk groups for targeted prevention and
29 treatment in Haiti.

30 **Methods**

31 We used cross-sectional data within the Haiti CVD Cohort Study, including 653 adults ≥ 40 years without
32 known history of CVD and with complete data. Six CVD risk prediction models were compared: pooled
33 cohort equations (PCE), adjusted PCE with updated cohorts, Framingham CVD Lipids, Framingham CVD
34 Body Mass Index (BMI), WHO Lipids, and WHO BMI. Risk factors were measured during clinical exams.
35 Primary outcome was continuous and categorical predicted 10-year CVD risk. Secondary outcome was
36 statin eligibility.

37 **Results**

38 Seventy percent were female, 65.5% lived on a daily income of ≤ 1 USD, 57.0% had hypertension, 14.5%
39 had hypercholesterolemia, 9.3% had diabetes mellitus, 5.5% were current smokers, and 2.0% had HIV.
40 Predicted 10-year CVD risk ranged from 3.9% in adjusted PCE (IQR 1.7-8.4) to 9.8% in Framingham-BMI
41 (IQR 5.0-17.8), and Spearman rank correlation coefficients ranged from 0.87 to 0.98. The percent of the
42 cohort categorized as high risk using the uniform threshold of 10-year CVD risk $\geq 7.5\%$ ranged from

43 28.8% in the adjusted PCE model to 62.0% in the Framingham-BMI model ($\chi^2 = 331$, p value < 0.001).

44 Statin eligibility also varied widely.

45 **Conclusions**

46 In the Haiti CVD Cohort, there was substantial variation in the proportion identified as high-risk and
47 statin eligible using existing models, leading to very different treatment recommendations and public
48 health implications depending on which prediction model is chosen. There is a need to design and
49 validate CVD risk prediction tools for low-middle income countries that include locally relevant risk
50 factors.

51 **Trial registration:** clinicaltrials.gov NCT03892265

52 **Keywords:** cardiovascular diseases, primary prevention, risk, global health, hypertension

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67 **Background**

68 Cardiovascular diseases (CVD) are rapidly increasing in low-middle income countries (LMICs), with
69 ischemic heart disease, stroke, and peripheral artery disease amounting to over 17 million deaths in
70 2017 (1). Furthermore, mortality and disability due to CVD have increased by 21.1% and 16.4%,
71 respectively, over the past ten years (1). Multiple risk factors contribute to the increase in CVD, including
72 high systolic blood pressure (SBP), hyperlipidemia, tobacco and alcohol use (2). In addition to known
73 modifiable risk factors such as diet, lack of physical activity, and smoking, many LMICs may have
74 additional structural factors for CVD risk such as heavy metal environmental pollution and increased
75 allostatic load related to the stress of poverty that are not captured in existing CVD risk prediction
76 models (3,4).

77 Accurate CVD risk prediction to target use of statins and antihypertensives in primary CVD prevention is
78 essential to reduce premature disease, especially in a LMIC country like Haiti where CVD leads mortality
79 at 26.5% of all adults deaths, and where there are significant resource-constraints. (5,6). However,
80 available CVD risk prediction models are built on predominantly Caucasian, high-income country
81 populations, and have not been evaluated in LMIC populations due to the paucity of rigorous cohorts
82 with hard CVD outcomes (7–9). Furthermore, model choice may have ramifications for which individuals
83 are identified as high risk and recommended for treatment, with divergent cost and public health
84 implications.

85 The aim of this study is to compare the estimated 10-year risk of CVD across six commonly used CVD
86 prediction models, and identify high-risk groups for targeted statins. By applying these models to a
87 population-based cohort in Haiti, we hope to inform which CVD risk prediction model might best be
88 used in a LMIC context.

89 **Methods**

90 **Study Design**

91 We used cross-sectional data within the Haiti CVD Cohort Study, a population-based cohort in Port-au-
92 Prince selected using multistage random sampling with a previously described protocol (clinicaltrials.gov
93 NCT03892265) (10). We included 776 adults ≥ 40 years enrolled between March 2019 to April 2020.
94 Participants already on a statin ($n = 11$), with history of angina, myocardial infarction, stroke ($n = 69$), or
95 with missing data required for risk prediction ($n = 72$) were excluded given the focus on primary
96 prevention (**Supplemental Figure 1**).

97 The study was conducted at the Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections
98 Opportunistes clinics (GHESKIO), a medical organization that has operated continuously over four
99 decades in Haiti to provide clinical care and conduct research on HIV and chronic diseases.

100 **Measurements**

101 Demographic data (age, sex, education, income) and health behaviors (smoking status, physical activity)
102 were collected during an enrollment survey using standardized WHO STEPs instruments (11). Clinical
103 data, including height, weight, and blood pressure (BP), were measured during a physical exam with a
104 study physician or nurse at enrollment.

105 BP was measured using the automated Omron HEM-907 machine with an appropriate cuff size (bladder
106 encircling at least 80% of arm), after the participant had been seated in a quiet space for five minutes
107 with both feet on the ground and their arm supported at heart level (11,12). Three BP measurements
108 were taken on the left arm separated by one-minute intervals. In accordance with WHO guidelines, the
109 second and third BP measurements were averaged for all analyses (11).

110 Medical history and diagnoses (hypertension, hyperlipidemia, diabetes, myocardial infarction, angina,
111 stroke, HIV) were determined based a history and physical exam performed by a trained study physician,
112 and direct clinical or laboratory measurement where applicable ([Supplemental Table 1](#)).

113 **CVD Risk Assessment**

114 Six models were compared: the Pooled Cohort Equations (PCEs) (7), an adjusted PCE (aPCE)
115 incorporating updated cohorts with more African Americans (13), Framingham CVD Lipids (8),
116 Framingham CVD Body Mass Index (BMI) (8), WHO-Lipids (9), and WHO-BMI (9). These models were
117 chosen because they are widely used, frequently compared in existing literature, and most include
118 people of African descent. The systematic coronary risk evaluation (SCORE) model based on European
119 cohorts was not used given it only predicts fatal CVD outcomes.

120 Underlying equations and coefficients were extracted from published literature and applied to the
121 cohort (7–9,13) ([Supplemental Table 2-4](#)).

122 **Outcomes and Statistical Analysis**

123 The primary outcome was predicted 10-year risk of CVD as 1) a continuous score and 2) a categorical
124 score (low, intermediate, high). Categorical scores were calculated using two methods: uniform
125 thresholds (low <5%, intermediate 5 to 7.5%, high \geq 7.5%), and model specific thresholds (PCE and
126 adjusted PCE: <5%, 5 to 7.5%, \geq 7.5%; Framingham-Lipids and Framingham-BMI: <10%, 10 to 20%, \geq
127 20%; WHO-Lipids and WHO-BMI: <5%, 5 to 20%, \geq 20%). Model specific thresholds exist due to
128 differences in equation derivation, including measured CVD outcomes (7–9). Spearman rank correlation
129 coefficients were used to measure concordance between models' ranked order of participants from
130 lowest to highest risk, ranging from -1 (perfect discordance) to +1 (perfect concordance). Categorical
131 scores were compared using chi square tests of independence. Discordance was defined as participants
132 categorized as low risk by one score, but high risk by another.

133 For participants categorized as high-risk using uniform thresholds, the underlying risk factors were
134 summarized using medians, counts, and percentages to understand what risk factors were leading to
135 the high-risk scores.

136 The secondary outcome was statin eligibility, based on model specific thresholds and criteria
137 (Supplemental Table 5). Statin eligibility was compared using chi square tests of independence. 95%
138 confidence intervals (CI) were calculated using one sample proportions test.

139 All analyses were conducted using R, version 4.0.2.

140 Results

141 Out of 1,435 adults ≥ 18 years enrolled during the study period, 1363 (95.0%) had complete data and
142 653 (45.5%) met study eligibility criteria. Of these 653, 70.4% were female, 65.5% lived on a daily
143 income of ≤ 1 USD, 57.0% had hypertension, 14.5% had hypercholesterolemia, 9.3% had diabetes
144 mellitus, 5.5% were current smokers, and 2.0% had HIV (Table 1). Overall, 38.1% had a low-density
145 lipoprotein cholesterol greater than 130 mg/dL, 42.7% had a systolic blood pressure ≥ 140 mmHg, and
146 26.6% had a diastolic blood pressure ≥ 90 mmHg.

147 Predicted 10-year CVD Risk

148 Using a continuous score, median predicted 10-year CVD risk ranged from 3.9% in the adjusted PCE
149 model (IQR 1.7-8.4) to 9.8% in the Framingham-BMI model (IQR 5.0-17.8) (Table 2). Using the Spearman
150 rank correlation coefficient, we assessed the concordance between how each model ranked each
151 individual participant in order from lowest risk to highest risk in pairwise comparisons. Spearman
152 coefficients showed high concordance between models, ranging from 0.87 (Framingham-Lipids vs WHO-
153 BMI) to 0.98 (PCE vs adjusted PCE).

154 However, categorization of individuals into risk groups using uniform thresholds showed extremely wide
155 variability. The percent of the cohort categorized as high-risk ranged from 28.8% in the adjusted PCE
156 model to 62.0% in the Framingham-BMI model ($\chi^2 = 331$, p value < 0.001) (Fig 1A). Under uniform
157 thresholds, 186 participants had discordant scores (categorized as high risk by one score, but low risk by
158 another). The most common pattern was categorization as high risk by Framingham-lipids or
159 Framingham-BMI and low risk by another model (185 out of 186 discordant participants).

160 Using model specific thresholds resulted in similarly wide variability in risk categorization (Table 2, Fig
161 1B). The percent of the cohort categorized as high-risk ranged from 2.3% in WHO-BMI to 44.0% in PCE
162 ($\chi^2 = 712$, p value < 0.001). Under model specific thresholds, 70 participants had discordant scores, with
163 the most common pattern as high risk by PCE and low risk by another model (68 out of 70 discordant
164 participants).

165 Risk Factor Distribution in High-Risk Category and Statin Eligibility

166 The risk factor distribution of age, sex, comorbidities, SBP, total cholesterol, and HDL cholesterol for
167 participants with high 10-year CVD risk are summarized in Table 3. The median age ranged from 60 to
168 66, and percent female was 54.3% to 64.1%, reflecting the overall cohort sex breakdown. Diabetes and
169 current smoking were not common (< 20% and < 15%, respectively) in the high-risk groups. However,
170 SBP was relatively high. Treated SBP, or participants taking antihypertensive medications, ranged from a
171 median of 152 to 162 mmHg, and untreated SBP ranged from a median of 142 to 158 mmHg. Total
172 cholesterol was also high, ranging from a median of 197 to 202 mg/dL.

173 Using model specific thresholds, statin eligibility varied from 2.3% (95% CI 1.4% to 3.7%) with WHO-BMI
174 to 44.9% (95% CI 41.1% to 48.7%) with PCE ($\chi^2 = 513$, p value < 0.001) (Table 2).

175 Discussion

176 Correctly identifying high-risk patients allows for targeted interventions for primary prevention of CVD
177 and treatment of underlying risk factors. In the Haiti CVD Cohort, we found substantial variation in the
178 proportion identified as high-risk using existing models, ranging from 28.8% to 62.0% across models
179 using uniform thresholds. Anywhere from 2.3% to 44.9% of participants were eligible for statins, leading
180 to very different treatment recommendations and public health implications depending on which
181 prediction model is chosen.

182 In LMIC, comparison of predicted risk in global cohorts using multiple models shows similar
183 heterogeneity to our findings. In Brazil, an analysis comparing PCE to Framingham-Lipids in an all male
184 cohort revealed Framingham categorized 5.5% of men as high-risk, while PCE categorized none as high-
185 risk (14). In a cohort of HIV-infected patients in Botswana, PCE classified 14.1% as high risk while
186 Framingham classified only 2.6% (15).

187 Existing CVD risk models are built on largely Caucasian populations, and may not be accurate for a
188 majority black LMIC population like Haiti or many sub-Saharan African countries. Traditional methods
189 using Cox proportional hazards may overfit the data on small subgroups like African Americans, leading
190 to inaccurate predictions, and require assumptions about proportional hazards which may not be true
191 (13). Newer statistical techniques, like machine learning, may avoid these limitations and integrate a
192 larger breadth of data (16). Cohorts representative of LMIC with hard CVD outcomes are also needed to
193 supply accurate underlying data.

194 There is an urgent need to design and validate CVD risk prediction tools in LMICs that include locally
195 relevant risk factors reflecting disease pathology, and usability in low-resource settings. While ischemic
196 heart disease accounts for the majority of CVD in high income countries (HIC), nonatherosclerotic
197 stroke, hypertensive heart disease, and nonischemic cardiomyopathies are more common in LMIC (17).
198 In our cohort, examining the high-risk group across models showed hypertension was relatively

199 common, while diabetes and smoking were not. Designing new CVD risk models will also require a focus
200 on usability. Lipids are not routinely available in many places (18), making non-lab based methods such
201 as those using BMI more feasible. While online CVD risk calculators are widely available in HIC, lack of
202 reliable internet and friction of integration into busy workflows suggest paper based wallcharts, such as
203 produced by the WHO, may work better in LMIC.

204 To achieve desired health outcomes, CVD risk prediction must be translated into successful action,
205 involving multisector action from health systems, health care providers, and patients. Statin accessibility
206 is low in many LMICs. Based on the WHO Health Action International survey, statins are not on the
207 essential medicine list of 34% of countries, including Haiti (19,20). In Haiti, a 2011 survey showed
208 atorvastatin and simvastatin were available in retail pharmacies, but rarely in public or nonprofit
209 pharmacies, and expensive (21). The lowest paid government worker would need 2.6 days wages to pay
210 for a 1 month supply of statins if bought from a public sector pharmacy, and 13.7 day wages if brought
211 from a retail pharmacy (21). Lower availability and affordability of essential CVD meds have been
212 associated with higher risk of major adverse cardiovascular events and mortality (HR 1.25, 95% CI 1.08
213 to 1.50) (22).

214 Strengths of this study include it's design as a population-based cohort, rigorous BP measurement, and
215 standardized lipid measurement. Limitations include the exclusion of young participants < 40 for whom
216 traditional CVD risk models do not apply, and the lack of hard CVD outcomes to conduct predicted
217 versus observed comparisons.

218 In summary, across six commonly used CVD risk prediction models, there was substantial variation in
219 identification of high-risk participants using both uniform, and model specific thresholds. Locally
220 relevant CVD risk prediction models are needed in LMIC, combined with health systems strengthening to
221 increase treatment availability and affordability.

222

223

224 **Table 1: Demographic and clinical characteristics of Haiti CVD Cohort (N = 653)**

	N (%), or median [IQR]
Female	460 (70.4)
Age, median [IQR], y	54 [47, 62]
Education, primary or lower	391 (59.9)
Works for pay	231 (35.4)
Income (daily), ≤1 USD	428 (65.5)
Comorbidities*	
Hypertension	372 (57.0)
On treatment	143 (21.9)
Hypercholesterolemia	95 (14.5)
On treatment	0
Diabetes Mellitus	61 (9.3)
On treatment	32 (4.9)
HIV	13 (2.0)
Smoking, current	36 (5.5)
Physical Activity, ≤ 150 min / week (low)	370 (56.7)
Alcohol intake, more than 1 drink a day (moderate-high)	9 (1.4)
BMI ≥ 30 kg/m²	155 (23.7)
Cholesterol	
HDL Cholesterol < 40 mg/dL	137 (21.0)
LDL Cholesterol ≥130 mg/dL	249 (38.1)
Blood Pressure	
SBP ≥ 140 mmHg	279 (42.7)
SBP ≥ 130 mmHg	373 (57.1)
DBP ≥ 90 mmHg	174 (26.6)
DBP ≥ 80 mmHg	326 (49.9)

225 Legend: IQR = interquartile range. * Definitions available in Supplement.

226

227

228

229

230

231

232

233

234

235

236 **Table 2: Predicted 10-year CVD risk in Haiti CVD Cohort**

	Haitian cohort (N = 653)
CVD Risk Estimation Method	N (%)
Pooled Cohort Equations (PCE)	
Median (25th to 75th percentile)	6.6 [2.7, 13.1]
Low risk (<5%)	272 (41.7)
Intermediate (5 to <7.5%)	94 (14.4)
High (≥7.5%)	287 (44.0)
Statin eligibility*	293 (44.9)
adjusted Pooled Cohort Equations (adjusted PCE)	
Median (25th to 75th percentile)	3.9 [1.7, 8.4]
Low risk (<5%)	385 (59.0)
Intermediate (5 to <7.5%)	80 (12.3)
High (≥7.5%)	188 (28.8)
Statin eligibility*	211 (32.3)
Framingham-Lipids	
Median (25th to 75th percentile)	8.7 [4.5, 16.6]
Low (<10%)	361 (55.3)
Intermediate (10 to <20%)	170 (26.0)
High (≥20%)	122 (18.7)
Statin eligibility*	183 (28.0)
Framingham-BMI	
Median (25th to 75th percentile)	9.8 [5.0, 17.8]
Low (<10%)	330 (50.5)
Intermediate (10 to <20%)	177 (27.1)
High (≥20%)	146 (22.4)
Statin eligibility*	191 (29.2)
WHO-Lipids	
Median (25th to 75th percentile)	5.0 [2.0, 9.0]
Low risk (<5%)	310 (47.5)
Intermediate-high-risk (5 to <20%)	316 (48.4)
High (≥20%)	27 (4.1)
Statin eligibility*	27 (4.1)
WHO-BMI	
Median (25th to 75th percentile)	5.0 [3.0, 8.0]
Low risk (<5%)	313 (47.9)
Intermediate-high-risk (5 to <20%)	325 (49.8)
High (≥20%)	15 (2.3)
Statin eligibility*	15 (2.3)

237 Legend: * statin eligibility criteria by each model is detailed in the Supplement. 95% CI calculated using
 238 one sample proportions test.

239

240 **Table 3: Risk factor distribution in high-risk category, using uniform thresholds**

	PCE	adjusted PCE	Framingham-Lipids	Framingham-BMI	WHO-Lipids	WHO-BMI
Percent of cohort categorized as high-risk by risk calculator	44.0%	28.8%	57.1%	62.0%	30.6%	30.6%
n	287	188	373	405	200	200
Female, n (%)	182 (63.4)	102 (54.3)	239 (64.1)	254 (62.7)	123 (61.5)	128 (64.0)
Age, median [25th to 75th percentile], y	63 [58, 69]	64 [58, 71]	60 [54, 67]	60 [53, 66]	66 [61, 71]	66 [62, 71]
Diabetes Mellitus, n (%)	44 (15.3)	35 (18.6)	55 (14.7)	55 (13.6)	36 (18.0)	18 (9.0)
Current smoker, n (%)	29 (10.1)	23 (12.2)	31 (8.3)	32 (7.9)	24 (12.0)	22 (11.0)
SBP treated, median [25th to 75th percentile], mmHg	156 [146, 176]	160 [148, 178]	153 [143, 172]	152 [142, 172]	162 [151, 179]	162 [151, 180]
SBP not treated, median [25th to 75th percentile], mmHg	145 [132, 160]	158 [144, 172]	143 [130, 156]	142 [128, 156]	145 [132, 164]	146 [132, 165]
Total Cholesterol, median [25th to 75th percentile], mg/dL	202 [175, 224]	202 [178, 223]	202 [177, 223]	197 [171, 220]	202 [180, 224]	200 [178, 222]
HDL Cholesterol, median [25th to 75th percentile], mg/dL	47 [41, 55]	47 [40, 55]	47 [41, 55]	47 [41, 56]	50 [43, 59]	50 [43, 58]

241 Legend: A uniform threshold of 10-year CVD risk \geq 7.5% was used to identify high-risk participants.

242

243

244

245

246

247

248

249

250

251

252 **Figure 1: Predicted 10-year CVD risk categorizations by model**

253 Legend: Figure shows proportion of cohort categorized as low, intermediate, or high-risk. Panel A uses a

254 uniform thresholds for low, intermediate, and high-risk: <5%, 5 to 7.5%, and $\geq 7.5\%$. Panel B uses model

255 specific thresholds for low, intermediate, and high-risk: PCE <5%, 5 to 7.5%, $\geq 7.5\%$; adjusted PCE <5%, 5

256 to 7.5%, $\geq 7.5\%$; Framingham-Lipids <10%, 10 to 20%, $\geq 20\%$; Framingham-BMI <10%, 10 to 20%, $\geq 20\%$;

257 WHO-Lipids <5%, 5 to 20%, $\geq 20\%$; WHO-BMI <5%, 5 to 20%, $\geq 20\%$.

258

259 **List of abbreviations**

260 aPCE: adjusted pooled cohort equations

261 BMI: body mass index

262 BP: blood pressure

263 CVD: cardiovascular disease

264 DBP: diastolic blood pressure

265 GHESKIO: Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunistes clinics

266 IQR: interquartile range

267 LMIC: low middle income countries

268 PCE: pooled cohort equations

269 SBP: systolic blood pressure

270 SCORE: systematic coronary risk evaluation model

271 WHO: World Health Organization

272 **References**

- 273 1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality
274 for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the
275 Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1736–88.
- 276 2. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of
277 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195
278 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study
279 2017. *Lancet*. 2018 Nov 10;392(10159):1923–94.
- 280 3. Lanphear BP, Rauch S, Auinger P, Allen RW, Hornung RW. Low-level lead exposure and mortality in
281 US adults: a population-based cohort study. *The Lancet Public Health*. 2018 Apr 1;3(4):e177–84.
- 282 4. Beaglehole Robert, Reddy Srinath, Leeder Stephen R. Poverty and Human Development.
283 *Circulation*. 2007 Oct 23;116(17):1871–3.
- 284 5. GBD Compare | IHME Viz Hub [Internet]. [cited 2021 Jan 22]. Available from:
285 <http://vizhub.healthdata.org/gbd-compare>
- 286 6. Feigin VL, Brainin M, Norrving B, Gorelick PB, Dichgans M, Wang W, et al. What Is the Best Mix of
287 Population-Wide and High-Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease
288 Prevention? *J Am Heart Assoc*. 2020 Feb 4;9(3):e014494.
- 289 7. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA
290 guideline on the assessment of cardiovascular risk: a report of the American College of
291 Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014 Jun
292 24;129(25 Suppl 2):S49-73.
- 293 8. D'Agostino Ralph B., Vasan Ramachandran S., Pencina Michael J., Wolf Philip A., Cobain Mark,
294 Massaro Joseph M., et al. General Cardiovascular Risk Profile for Use in Primary Care. *Circulation*.
295 2008 Feb 12;117(6):743–53.
- 296 9. Kaptoge S, Pennells L, Bacquer DD, Cooney MT, Kavousi M, Stevens G, et al. World Health
297 Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global
298 regions. *The Lancet Global Health*. 2019 Oct 1;7(10):e1332–45.
- 299 10. Lookens J, Tymejczyk O, Rouzier V, Smith C, Preval F, Joseph I, et al. The Haiti cardiovascular
300 disease cohort: study protocol for a population-based longitudinal cohort. *BMC Public Health*
301 [Internet]. 2020 Nov 1 [cited 2020 Nov 9];20. Available from:
302 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603639/>

- 303 11. WHO. WHO STEPS surveillance manual: The WHO STEPwise approach to chronic disease risk factor
304 surveillance [Internet]. Geneva: WHO; 2017. Available from:
305 <https://www.who.int/ncds/surveillance/steps/manual/en/index3.html>
- 306 12. Agarwal R. Implications of Blood Pressure Measurement Technique for Implementation of Systolic
307 Blood Pressure Intervention Trial (SPRINT). *J Am Heart Assoc*. 2017;6(2).
- 308 13. Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min Y-I, Basu S. Clinical Implications of
309 Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk. *Ann*
310 *Intern Med*. 2018 Jul 3;169(1):20.
- 311 14. Guerra-Silva NMM, Santucci FS, Moreira RC, Tashima CM, Melo SCCS de, Pereira LRL, et al.
312 Coronary disease risk assessment in men: Comparison between ASCVD Risk versus Framingham.
313 *International Journal of Cardiology*. 2017 Feb 1;228:481–7.
- 314 15. Mosepele M, Hemphill LC, Palai T, Nkele I, Bennett K, Lockman S, et al. Cardiovascular disease risk
315 prediction by the American College of Cardiology (ACC)/American Heart Association (AHA)
316 Atherosclerotic Cardiovascular Disease (ASCVD) risk score among HIV-infected patients in sub-
317 Saharan Africa. *PLoS ONE*. 2017;12(2):e0172897.
- 318 16. Kakadiaris IA, Vrigkas M, Yen AA, Kuznetsova T, Budoff M, Naghavi M. Machine Learning
319 Outperforms ACC/AHA CVD Risk Calculator in MESA. *J Am Heart Assoc* [Internet]. 2018 Nov 11
320 [cited 2020 Mar 3];7(22). Available from:
321 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404456/>
- 322 17. Kwan GF, Mayosi BM, Mocumbi AO, Miranda JJ, Ezzati M, Jain Y, et al. Endemic Cardiovascular
323 Diseases of the Poorest Billion. *Circulation*. 2016 Jun 14;133(24):2561–75.
- 324 18. Mendis S, Al Bashir I, Dissanayake L, Varghese C, Fadhil I, Marhe E, et al. Gaps in capacity in
325 primary care in low-resource settings for implementation of essential noncommunicable disease
326 interventions. *Int J Hypertens*. 2012;2012:584041.
- 327 19. Husain Muhammad Jami, Datta Biplab Kumar, Kostova Deliana, Joseph Kristy T., Asma Samira,
328 Richter Patricia, et al. Access to Cardiovascular Disease and Hypertension Medicines in Developing
329 Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. *Journal of*
330 *the American Heart Association*. 2020 May 5;9(9):e015302.
- 331 20. Joseph FJ-J. LISTE NATIONALE DES MÉDICAMENTS ESSENTIELS. Direction de la Pharmacie, du
332 Médicament et de la Médecine Traditionnelle; 2012 May p. 74.
- 333 21. Chahal HS, St. Fort N, Bero L. Availability, prices and affordability of essential medicines in Haiti. *J*
334 *Glob Health* [Internet]. 2013 Dec [cited 2021 Feb 15];3(2). Available from:
335 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868824/>
- 336 22. Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, et al. Availability and
337 affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and
338 low-income countries. *BMJ Global Health*. 2020 Nov 1;5(11):e002640.

339

340

341

342

343 **Declarations**

344 **Ethics approval and consent to participate**

345 This study was approved by institutional review boards at Weill Cornell Medicine and Groupe Haitien
346 d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) (record number 1803019037),
347 with written participant consent.

348 **Consent for publication**

349 Not applicable

350 **Availability of data and materials**

351 Researchers who provide a methodologically sound proposal may have access to a subset of
352 deidentified participant data, with specific variables based on the proposal. Proposals should be directed
353 to the principal investigator at mam9365@med.cornell.edu. To gain access, data requestors will need to
354 sign a data access agreement. Data are available following publications through 3 years after publication
355 and will be provided directly from the PI.

356 **Competing interests**

357 JLP, VR, JWP, MLM report a grant from NHLBI R01HL143788. The remaining authors declare they have
358 no conflicts of interest.

359 **Funding support and role of funder**

360 Funding for this study comes from the National Heart, Lung, and Blood Institute, grant number
361 R01HL143788. The funders had no role in the study design or execution of this protocol.

362 **Author Contributions**

363 This study was conceived by LDY and MLM. Project administration, and data curation were completed
364 by LDY, JLP, VR, JWP, MLM. Formal analysis was completed by LDY. Investigation, methodology, and
365 interpretation were completed by LDY, JLP, VR, MT, JWP, MMS, and MLM. LDY and MLM wrote the
366 initial draft. All authors participated in reviewing and editing the manuscript.

367 All authors have read, and confirm that they meet, ICMJE criteria for authorship.

368 **Acknowledgements**

369 We acknowledge the valuable input from the Haitian College of Cardiology, the community health
370 workers who help with data collection, the data management team (Stephano St-Preux, Olga Tymejczyk,
371 Miranda Metz), and the study participants for entrusting us with their care.


372 **Author access to data**

373 LDY and MLM had full access to all the data in the study and take responsibility for the integrity of the
374 data and the accuracy of the data analysis. LDY conducted the data analysis.


375

A

Risk Calculator

CVD Risk Score ■ Low ■ Intermediate ■ High**B**

Risk Calculator

CVD Risk Score ■ Low ■ Intermediate ■ High